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Abstract
To evaluate whether myocardial performance index detects a subclinical impairment of left
ventricular systolic and diastolic function in patients with early stage of type 2 diabetes, without
coronary artery disease, with or without hypertension. Furthermore, to evaluate whether some
echocardiographic parameters relate to the metabolic control. Fourty-five consecutive male
patients (mean age 52.5 years) with type 2 diabetes mellitus of recent onset (23 hypertensives and
22 normotensives) and 22 age matched healthy controls males were analysed. All participants had
normal exercise ECG. All subjects underwent standard and Doppler echocardiography for the
assessment of the isovolumic Doppler time interval and Doppler-derived myocardial performance
index. In all diabetic patients a glycated haemoglobin test was also performed.
No differences were observed in blood pressure, heart rate, and conventional echocardiographic
parameters comparing the 2 subgroups of diabetic patients and the controls. Myocardial
performance index was significantly higher in diabetic patients independently of the hypertension
occurrence, compared to the controls (0.49 and 0.49 diabetic normotensives and hypertensives
respectively vs. 0.39, p < 0.01). Myocardial performance index correlated to glycated haemoglobin
significantly (r = 0.37, p < 0.01) in both diabetic subgroups. Thus, an early involvement of left
ventricular performance was shown by myocardial performance index in patients with type 2
diabetes of recent onset without coronary artery disease, independently of the hypertension
presence. These abnormalities can provide a feasible approach to detect a pre-clinical diabetic
cardiomyopathy and could be useful for an indirect assessment of the metabolic control.
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Background
A primary diabetic cardiomyopathy represents a high risk
factor of heart failure in the absence of ischemic, valvular
and hypertensive heart disease in the diabetic population
[1-3]. Diabetic cardiomyopathy is characterized by an
early left ventricular (LV) diastolic dysfunction and a late
LV systolic dysfunction. At conventional echocardiogra-
phy LV diastolic dysfunction has been documented also in
subjects with impaired glucose tolerance [4] and a short
duration of type 2 diabetes mellitus [5]. Unquestionably,
an early detection of LV damage is a major goal for the
prevention of cardiac disease in the diabetic population.
Tei et al [6] described a simple, reproducible Doppler
derived Myocardial Performance Index (MPI) able to
reflect both LV systolic and diastolic function. MPI is diag-
nostic in patients with heart failure [7,8] and in individu-
als with overt cardiac disease who have positive risk
factors for coronary artery disease [9,10]. Furthermore, it
has a prognostic value in patients with myocardial infarc-
tion [11], and in those with cardiac amyloidosis [12]. Lit-
tle is known about the MPI impact in patients with
diabetes mellitus of recent onset and without coronary
artery disease. The aim of this study was to evaluate
whether MPI is able to detect a subclinical LV involvement
in patients with a short duration of type 2 diabetes melli-
tus without coronary artery disease, with and without
hypertension, and whether echocardiographic functional




The study population consisted of 45 consecutive male
patients with type 2 diabetes mellitus of recent onset (23
hypertensives and 22 normotensives) and 22 healthy con-
trols males. The patient population was recruited from the
Operative Unit of Internal Medicine, Montecchio Emilia
Hospital, IT between July 2006 and December 2006. All
partecipants had normal exercise ECG and none was a
smoker. All subjects underwent standard and Doppler
echocardiography and all diabetic patients also a glycated
haemoglobin (HbA1c) test. Diabetes mellitus was diag-
nosed according to the criteria of the American Diabetes
Association [13], including fasting plasma glucose level ≥
126 mg/dl on at least two occasions. HbA1c was deter-
mined by the HPLC method. Blood sample for analysis
was obtained after 8-hours minimum overnight fast and
before oral antidiabetic drugs. Hypertension was defined
as recommended from the Seventh Report of the Joint
National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure [14] or treat-
ment with antihypertensive drugs for a known diagnosis
of hypertension. Body mass index (BMI) was calculated as
weight in kilograms divided by the square of height in
meters. Obese where those patients who had a BMI > 30
Kg/m2. Patients with history of myocardial infarction,
chronic stable angina pectoris, previous coronary revascu-
larization, regional wall-motion abnormalities in rest
echocardiography, significant valvular disease at echocar-
diography, significant rest ECG abnormalities suggestive
of myocardial ischemia, symptoms or ECG signs of
ischemia on exercise stress test, arrhythmias, congestive
heart failure, and chronic obstructive pulmonary disease
were excluded from the study. The local medical Ethic
Committee approved the study protocol. Written
informed consent was obtained from all patients.
Echocardiography
All subjects underwent two-dimensional and Doppler
echocardiogram according to the recommendations of the
American Society of Echocardiography [15]. Recordings
were taken from patients standard left lateral decubitus
position in expiratory apnoea or quiet breathing by using
a multi-hertz sector probe (2–4 MHz) of a Sequoia 512
(Siemens Acuson, Mountain View, California) and stored
in the computer of the ultrasonic unit. LV dimensions
were measured with M-mode using a leading edge-to-edge
convention. The measurements included intraventricular
septal thickness (IVS), posterior wall thickness (PW), left
ventricular diameter at the end of diastole (LVEDD) and
systole (LVESD) respectively. Left ventricular relative wall
thickness was calculated as (IVS + PW)/LVEDD. Left ven-
tricular mass (LVM) was calculated using the Penn-con-
vention and indexed to Body Surface Area (LVM/BSA)
[16,17]. LV end-diastolic and end-systolic volume as well
as the ejection fraction (EF) were calculated according to
the biplane Simpson rule. Fractional shortening (FS) was
assessed as a percent ratio: (LVDD-LVDS)/LVDD. LV fill-
ing was assessed with pulse-wave Doppler echocardiogra-
phy. Measurements were obtained with the transducer in
the apical 4-chamber view, and with the Doppler beam
aligned as perpendicular as possible to the plane of the
mitral annulus. To obtain mitral flow velocities, Doppler
sample volume was placed between the tips of mitral leaf-
lets during diastole. From pulsed Doppler the mitral
inflow E-wave deceleration time (DT), peak velocity (pv)
and time velocity integral (tvi) of E and A wave and E/A
ratios were assessed. These measurements were detected
during the second phase of Valsalva manoeuvre in order
to discriminate subjects with normal diastolic function
from subject with "pseudonormalized" pattern [18].
Overall LV function was assessed using the Tei index,
defined as the sum of isovolumetric relaxation and con-
traction times (IRT and ICT respectively) divided by ejec-
tion time [19] which can be obtained from pulsed
Doppler recordings of mitral inflow. LV outflow was
recorded from the apical long-axis view with pulsed-wave
Doppler with the sample volume positioned just below
the aortic valve (Figure 1). Other aspects of this technique
have been considered in our previous studies [20,21]. AllCardiovascular Ultrasound 2008, 6:27 http://www.cardiovascularultrasound.com/content/6/1/27
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of the echocardiographic measurements were performed
by the same experienced cardiologist (P. P.) who was una-
ware of the patients' clinical data.
Statistics
All statistical analyses were carried out with SPSS for Win-
dows release 15.0 (SPSS Inc., Chicago, IL, USA). Data are
expressed as means + standard deviation. Comparison
among the 3 groups for various parameters was per-
formed by 1-way analysis of variance (ANOVA) and the
post-hoc Tukey test for multiple comparisons, and two
tailed Student's t test for paired data were applied to eval-
uate differences between controls and patient groups. The
relationship between parameters were evaluated by
means of simple linear regression data analysis. The P-val-
ues below 0.05 was considered statistically significant.
Results
Baseline Characteristics
The clinical characteristics of the studied population are
shown in Table 1. The two groups of diabetic patients
were similar for age, diabetes mellitus duration, type of
antidiabetic treatment, HbA1c, fasting blood glucose,
blood pressure and heart rate at the time of the medical
check. Blood pressure and heart rate were lower in the
control group.
Standard Echocardiographic Parameters
The echocardiographic characteristics of the three study
groups are listed in Table 2. LV diameters, volumes, EF,
fractional shortening and wall thicknesses were superim-
posable comparing diabetic normotensive to diabetic
hypertensive patients. Diabetic patients showed higher LV
diameter, LV volumes, wall thicknesses and LV mass. On
the contrary, they showed lower fractional shortening and
EF (Table 2). These differences were more clear when dia-
betes was associated to hypertension.
The diastolic function, evaluated as the mean of E/A ratios
and DT, was similar comparing diabetic normotensive to
diabetic hypertensive patients but was significantly differ-
ent when both the diabetic groups of patients were com-
pared to normal subjects (Epv/Apv 1.0 in both diabetic
populations vs. 1.4 in controls, p < 0.01; DT 182 msec and
190 msec in diabetics respectively normotensives and
hypertensives vs. 139 in controls, p < 0.01), although
within the normal range (Table 3). The prevalence of
abnormal diastolic filling was equal in the diabetic hyper-
tensive patients (7 patients with impaired relaxation) and
Relationship between Myocardial Performance Index and gly- cated haemoglobin in all diabetic patients Figure 2
Relationship between Myocardial Performance Index 
and glycated haemoglobin in all diabetic patients.
Flow Doppler at the mitral valve and at the LV outflow tract Figure 1
Flow Doppler at the mitral valve and at the LV out-
flow tract. Measurements of the time intervals of the Myo-
cardial Performance Index (MPI). The interval "a" is 
measured from the end to the onset of mitral inflow wave-
form; the interval "b" is the left ventricular outflow velocity 
tracing (ET). The MPI was calculated as (a - b)/b.Cardiovascular Ultrasound 2008, 6:27 http://www.cardiovascularultrasound.com/content/6/1/27
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diabetic normotensive patients (6 patients with impaired
relaxation).
MPI was significantly higher in both diabetic groups com-
pared to controls (Table 3). This was primarily due to a
significant prolongation of IRT (78 and 80 msec in diabet-
ics normotensives and hypertensives respectively vs. 62
msec in controls, p < 0.05). The MPI was similar in the
two diabetic groups independently of the diastolic dys-
function. MPI correlated to HbA1c significantly in all
patients (r = 0.37, p < 0.01) (Figure 2). In particular HbA1c
directly correlated to ICT (r = 0.29, p < 0.05) and inversely
with ET (r = - 0.29, p < 0.05). No correlations were found
between some clinical parameters (diabetes duration,
systolic and diastolic blood pressure, patients age) and
echocardiographic parameters (LV mass index, wall thick-
ness, LV EF or FS, E/A ratios and DT.
Discussion
In a previous study Mishra and coworkers have shown a
limited role for MPI in the assessment of cardiac function
in populations with multiple coronary risk factors but free
of clinical cardiovascular disease [22], although some
studies demonstrated an increase of MPI in type 2 diabetic
patients free of coronary artery disease [9,23]. To our
knowledge, our study is the first that identify the earliest
cardiac performance abnormalities at echocardiography
in a homogeneous group of type 2 diabetic patients with
short duration of disease without coronary artery disease,
independently of hypertension occurrence and diastolic
function. In both diabetic groups the mean E/A ratio was
lower compared to controls, although within the normal
range. MPI increase was mainly due to a prolongation of
IRT. Our data show that the global myocardial perform-
ance dysfunction may precede the diastolic dysfunction,
therefore it represents the earliest echocardiographic sign
evidence of diabetic cardiomyopathy. Several reports
attempted to determine the prevalence of LV diastolic dys-
function in middle-aged asymptomatic subjects with type
2 diabetes [24,25]. However, these studies, which used
Doppler assessment of transmitral flow velocity, could
have underestimated the prevalence of LV diastolic dys-
function, because they neglected to account for pseudo-
normal patterns of ventricular filling, which are often
noted in the evaluation of LV diastolic function [26]. In
our study, the diastolic parameters were detected during
the second phase of Valsalva manoeuvre in order to dis-
criminate subjects with normal diastolic function from
subject with "pseudonormalized" pattern.
The mechanisms behind LV performance dysfunction
remain largely unknown. In normotensive and free of
ischemic heart disease patients, the metabolic abnormali-
ties may play a major role. In fact, we found a correlation
between myocardial performance index and HbA1c (Fig-
ure 2). Nevertheless, the clinical value of this correlation,
although statistically significant, will be confirmed with a
prolonged follow-up and increasing the sample size. The
impact of the coexistence of diabetes and hypertension on
LV function has recently been investigated both in the
Table 1: Clinical and biochemical characteristics of controls and diabetic patients.
Parameters Diabetes mellitus (n. 22) Diabetes mellitus and hypertension (n. 23) Controls (n. 22)
Age (years) 52 ± 7 53 ± 8 53 ± 5
Obesity (%) 18 21 0
Hypertension (%) 0 100 0
Hypercholesterolemia (%) 14 22 0**
Smoking (%) 0 0 0
Family history of myocardial ischemia (%) 15 17 8†
Systolic blood pressure (mmHg) 127 ± 5§ 138 ± 14** 120 ± 14
Diastolic blood pressure (mmHg) 81 ± 7§§ 82 ± 9** 75 ± 7
Heart rate (bpm) 75 ± 7** 76 ± 10** 67 ± 8
Mean diabetes duration (months) 40 ± 18 36 ± 15 -
Fasting glucose (mg/dL) 167 ± 36§§ 138 ± 25 87 ± 8
HbA1c (%) 7.7 ± 2.2 7.0 ± 1.0 3.7 ± 2.2
Oral hypoglycaemic agents (%) 77 74 0
Diet therapy (%) 23 26 0
Anti-hypertensive theraphy (%)
ACE-inhibitor 9 65 -
Angiotensin receptor antagonist - 22 -
Diuretics - 22 -
Calcium channel blockers - 22 -
Beta-blockers - 17 -
**p < 0.01 diabetics vs controls; §p < 0.02 diabetic-normotensive patients vs diabetic-hypertensive patients; §§p < 0.03 diabetic-normotensive 
patients vs diabetic-hypertensive patients. HbA1c, glycated haemoglobin.Cardiovascular Ultrasound 2008, 6:27 http://www.cardiovascularultrasound.com/content/6/1/27
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Strong Heart study and the HyperGEN study [27-29],
where apparent implications of a specific diabetes effect
on LV relaxation of the myocardium were found in hyper-
tensive type 2 diabetic patients [27]. This can be due to
impaired glycemic control, microangiopathy or intersti-
tial accumulation of elastin and collagen which also
increase LV stiffness and mass in diabetic patients [30].
Ren et al demonstrated that short-term hyperglycaemia
modifies the cardiomyocites contraction and relaxation in
an experimental model of isolated ventricular myocites
[31]. In addition, a study of Fang et al performed on dia-
betic patients hyperglycaemia and insulin resistance are
able to induce functional and structural changes of cardi-
omyocites, which lead to progressive deterioration of
regional and global myocardial dynamics [32]. In our
study we used an echo approach for the evaluation of sub-
clinical myocardial involvement, that represents a main
advantage due to the radiation – free nature of ultrasound
[33].
Our findings may have important clinical implications to
the early identification of subclinical myocardial perform-
ance abnormalities with normal cardiac function at the
conventional echocardiography. MPI provides an easy
early phase index of diabetic cardiomyopathy that precede
diastolic dysfunction, which monitors the natural history
of the diabetic disease. Furthermore, MPI is useful for the
indirect assessment of the metabolic control or for sug-
gesting an early pharmacological treatment. Finally, MPI
detects whether such abnormalities can modify or revert
as a response to an optimal metabolic control and/or
pharmacological treatment. The early diagnosis of a pre-
clinical diabetic cardiomyopathy with MPI is useful for
the appropriate clinical testing of new therapeutic
approaches in the diabetic population.
A study limitation is represented by the patients sample,
which is limited in size. In addition, the diabetes therapy
was different in the two groups of patients although
according to the guidelines. Moreover, we know that the
exercise ECG in diabetic patients has a low sensitivity and
subclinical atherosclerosis cannot be fully excluded. How-
ever, our patients were asymptomatic, free of previous his-
tory of coronary artery disease and the diabetes was of
Table 3: Myocardial Performance Index and Doppler time intervals.
Parameters Diabetes mellitus Diabetes mellitus with hypertension Controls
LV MPI 0.49 ± 0.10* 0.49 ± 0.12** 0.39 ± 0.10
LV ICT (ms) 59 ± 22 60 ± 24 50 ± 11
LV IRT (ms) 78 ± 24† 80 ± 33† 62 ± 14
LV ET (ms) 281 ± 23 285 ± 25 295 ± 30
E-wave deceleration time (ms) 182 ± 51** 190 ± 59** 139 ± 16
Epv (cm/s) 67 ± 9* 71 ± 11 76 ± 16
Etvi (cm) 9 ± 2 9 ± 3 10 ± 2
Apv (cm/s) 70 ± 13** 76 ± 14** 57 ± 13
Atvi (cm) 6 ± 2 7 ± 2† 5 ± 2
Epv/Apv 1.0 ± 0.2 1.0 ± 0.2** 1.4 ± 0.3
Etvi/Atvi 1.5 ± 0.4** 1.4 ± 0.5** 2.0 ± 0.6
*p < 0.02 diabetics vs controls, **p < 0.01 diabetics vs controls, †p < 0.05 diabetics vs controls.
LV, left ventricle; MPI, myocardial performance index; ICT, isovolumic relaxation time; IRT, isovolumic contraction time; ET, ejection time; E, early 
diastolic filling wave; A, atrial contraction wave; pv, peak velocity; tvi, time velocity integral.
Table 2: Conventional echocardiographic variables in patients and controls.
Parameters Diabetes mellitus Diabetes mellitus with hypertension Controls
LV end-diastolic diameter (mm) 50 ± 5 51 ± 5** 46 ± 5
LV end-systolic diameter (mm) 31 ± 5 33 ± 5** 28 ± 4
Septal wall thickness (mm) 10 ± 1† 11.1 ± 1** 9 ± 1
Posterior wall thickness (mm) 10 ± 1** 10 ± 1** 9 ± 2
Relative wall thickness 0.42 ± 0.06 0.43 ± 0.06 0.40 ± 0.07
LV mass index (g/m2) 116 ± 25** 130 ± 22** 92 ± 23
LV fractional shortening (%) 36 ± 8 35 ± 6 39 ± 5
Ejection fraction (%) 64 ± 6 63 ± 6 64 ± 4
LV end-diastolic volume (ml) 96 ± 22 105 ± 24 97 ± 22
LV end-systolic volume (ml) 38 ± 11 44 ± 16 36 ± 12
**p < 0.01 diabetics vs controls,†p < 0.05 diabetic-normotensive patients vs diabetic-hypertensive patients.Cardiovascular Ultrasound 2008, 6:27 http://www.cardiovascularultrasound.com/content/6/1/27
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recent onset. We believe that the exercise test in patients
with these characteristics can represents a reliable test with
a higher sensitivity.
Beside, in common with other investigations on the MPI,
we did not evaluate the effects of abnormalities of late
diastolic compliance. However, when present, these are
associated with raised LV filling pressure, which would
shorten IRT and thus reduce the MPI, counterbalancing
the prolongation due to those of early diastole. Finally, no
outcome data are available at the moment.
Conclusion
In conclusion, subtle abnormalities of LV myocardial per-
formance are detected by means of MPI during the early
stage of type 2 diabetes, independently of the hyperten-
sion presence, and it broadens the spectrum of pre-clinical
diabetic cardiomyopathy.
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